We report here an effort to use molecular dynamics/free energy perturbation methodology to calculate relative binding affinities of two related drugs to DNA. Specifically, we focus on the relative binding free energies of distamycin (Dst) (7), who studied the base specificity ofthe interactions of daunomycin and acridine to DNA. Gago and Richards (8) and Hard and Nilsson (9) have also studied the base specificity of the interactions of netropsin with DNA. To our knowledge, this is the first reported effort to calculate the relative binding free energies of ligands to DNA.
mutating 2-ImD-i Dst reversibly. In the first case ligand 1 (site I) is mutated, in the second case llgand 2 (site II) is mutated, and in the third case both the ligands are mutated. These calculations show that at site I Dst has weaker binding affinity than 2-ImD by 0.7 kcal/mol, at site II Dst has stronger binding affinity than 2-ImD by 2.9 kcal/mol, and when occupying both site I and siteI, Dst binds with greater afflnity than 2-ImD by 1.8 kcal/mol. Recent experimental findings agree semiquantitatively (within 1 kcal/mol) with the cutions presented here. Hence the methodology presented here can be used to predict relative binding energies of two or more closely related molecules to DNA.
One of the goals of modeling drug-receptor interactions is to understand the molecular basis of action of ligands on proteins and DNA. Thus our hope is that we will be able to utilize computational methods and graphics to identify key determinants of the receptor-drug interactions and ultimately be able to develop better drugs that will exhibit greater affinity toward the receptor. Hence it is important to develop methods to predict binding affinities of new drug molecules to receptors. In the case ofDNA, one is interested in developing drugs that target a specific sequence. So far molecular dynamics (MD)/free energy perturbation (FEP) methodology has been successfully applied to predict binding affinities of drugs to proteins (1-3). There have been relatively few applications to DNA-drug interactions. The reason for this is that DNA is inherently more flexible than proteins, and also since DNA is a polyanion the treatment of electrostatic interactions is a challenging task. The large size ofthe system (DNA, ions, and water molecules) makes these simulations computationally intensive. Therefore, we present here a feasible methodology that can be effectively utilized to calculate relative association energies between any two or more similar ligands that bind to the same site on DNA.
Some recent studies of DNA-ligand interaction using MD include the drugs actinomycin D (4), spermine (5), and distamycin (Dst; ref. 6 ). Free energy calculations on DNAdrug complexes were presented by Cieplak et al. (7), who studied the base specificity ofthe interactions of daunomycin and acridine to DNA. Gago and Richards (8) and Hard and Nilsson (9) have also studied the base specificity of the interactions of netropsin with DNA. To our knowledge, this is the first reported effort to calculate the relative binding free energies of ligands to DNA.
One of the difficulties in applying free energy simulations on macromolecular systems is the long simulation times required to sample the possible conformations while maintaining equilibrium at each stage during the perturbation process. At present there is no way to assure that a simulation has been run long enough so that all possible conformations accessible to the system on the path of transformation have been sampled. In addition to sampling, there is the issue of the accuracy of force field parameters employed in these calculations and also several approximations involved in the handling of the long-range nonbonded interactions. Therefore, it is important to gain as much empirical experience with running FEP calculations under different conditions to study and understand the validity ofthe approximations involved in these calculations.
The binding of Dst and its variant 2-imidazole distamycin (2-ImD) to DNA represents not only an interesting system to understand DNA-drug interaction but also provides the opportunity to test the FEP methodology. This is because the mutations of the structure are small, involving only the mutation of the van Dst has three pyrrole rings, whereas its analog 2-ImD has an imidazole ring substituted for the central pyrrole ring (see Fig. 1 ). The pyrrole and the imidazole variant differ only in that the C-H is substituted by an N in the central ring. The starting conformation for these calculations is the solution structure of 2-ImDJ2-ImD-DNA minor groove complex (see Fig. 2 ) determined by Dwyer et al. (12) . In this complex both ligands point the imidazole N3 toward the N2 of G6. However only ligand 1 has N3 within the hydrogen-bonding distance from N2 of G6 (see II. We have carried out the following set of simulations to calculate free energy differences for the drug:
(i) 2-ImD Dst isolated in gas phase and (ii) 2-ImD = Dst isolated in solvent.
The following calculations were carried out on the complex in solution:
The thermodynamic cycles employed in thes simulations are given in Fig. 4 . The experimental binding afnities ofDst and 2-ImD to DNA are given by AG1, AG2, AG5, and AG2. These values can be related to AG3, AG4, AG6, and AG8 computed by FEP simulations. The relative binding affinities of these various complexes can be computed from
METHODS
The starting conformation for the FEP calculations was the NMR structure of the 2:1 complex of 2-ImD bound in the (12) . The starting geometry for Dst was obtained by taking 2-ImD from the NMR structure and then replacing N3 with the C-H group. The resultant geometry of Dst was then optimized using the STO-3G basis set (14) . The electrostatic charges for 2-ImD and Dst were then calculated by employing the STO-3G basis set and fitting the point charges that reproduce the quantum mechanical electrostatic potential. All ab initio calculations were carried out with Gaussian 92 (15) . The other force field parameters for Dst and 2-ImD not present in the force field of Weiner et al. (16) were assigned by analogy with chemically related groups (these and the charges are available on request from the authors).
The setup for MD/FEP calculations involved neutralizing the phosphate charges with Na+ ions placed at 3.6 A from the phosphate bisector. The drug complex was solvated by placing three site TIP3P water molecules (17) around the solute such that the solvent molecules were placed up to 10 A away along each of the rectangular coordinate axes and as close as 2.5 A from any given solute atom. We chose not to neutralize the positive charge on the Dst or 2-ImD to avoid computational complexities associated with highly mobile positive and negative ions in solution. Since the positive charge on the drug would be present in both the initial and final states of our calculation, we assume that the effects due to the unneutralized charges will cancel out and the perturbation on the system will be minimal. For isolated drug calculations, we solvated 2-ImD molecules by placing solvent molecules up to 12 A away and as close as 2.5 A from the solute.
We carried out the following equilibration protocol for relieving bad contacts between the solute and solvent and allowing the reordering of water with minimal distortion to the starting structure, before calculation of the free energy differences. We restrained the starting structure with a harmonic restraint of 25 kcal per mol per residue and carried out potential energy minimization for about 1000 cycles followed by MD at 300 K for about 3 ps. This was done to allow the water molecules to reorient and make favorable contacts with the solute. Then we released the restraints on the solute in five steps by reducing the restraint by 5 The FEP calculations on these equilibrated systems was carried out by using the thermodynamic windows method as described elsewhere (19) . The free energy perturbation was All our calculations were carried out using AMBER 4.0 (20 To avoid the unraveling of the ends, we imposed a weak harmonic restraint of 5.0 kcal per mol per residue on the terminal base pairs. To achieve structural reversibility in the FEP calculations we imposed a harmonic restraint of 5.0 kcal per mol per residue on the terminal atoms of the drug molecules. This was done to restrain the drug from sliding away from its initial structure but nonetheless allows enough flexibility around the site of mutation on the drug. In the case of the mutation of ligand 1 in the complex, we found that the free energy difference for the forward mutation was very similar to that computed without restraints, indicating that the restraints have not severely affected the results.
RESULTS AND DISCUSSION
The distances between N3 and D3 (the atomic label for the dummy atom in 2-ImD) in 2-ImD or C3 and H3 in Dst of ligands 1 and 2 and the amino proton of G6 are given in Table  1 . There is a weak hydrogen bond between N3 ofligand 1 and the amino proton (H21) of G6 (2.34 A) in the NMR structure, whereas for ligand 2 the corresponding distance is 3.58 A (see Fig. 3 ). These The total free energy changes and the relative binding affinities of each of the three mutations are given in Table 2 . In the case of the 2-ImDI2-ImDDNA --Dst-2-ImDLDNA mutation, we observe that Dst has a less favorable free energy of association than 2-ImD at site 1 by 0.65 kcal/mol ( Table 2 ). The lower affinity of Dst at this site is most likely due to the loss of the specific hydrogen bond interaction between the N3 and the amino proton of G6 and the steric repulsion between H3 and amino proton of G6. However, in the case of the 2-ImD*2-ImDJDNA -* 2-ImD-Dst-DNA mutation, Dst has more favorable free energy ofassociation than 2-ImD by 2.88 kcal/mol ( Table 2 ). The stronger binding of Dst at site II is probably due to the introduction of favorable van der Waals interactions between the pyrrole and the minor groove groups on DNA since 2-ImD at site II has more space between the N3 and H21 of G6 (see Table 1 ) than Dst. The more favorable desolvation energy of Dst will also contribute. Finally, in the third case, where 2-ImD2-ImDJDNA -+ Dst-Dst DNA mutation is carried out, the two Dst molecules bind with lower free energy than two 2-ImD molecules by 1.79 kcal/mol (Table 2 ). This, not surprisingly, is approximately the sum of the free energies for the two individual mutations. The first question addressed by the theory was the relative stability of 2-ImD-Dst-DNA versus Dst 2-ImD>DNA. Only the former is observed in equilibrium with Dst*Dst DNA when both ligands are present. This is consistent with our calculated free energy difference between 2-ImD-DstDNA and Dst-2-ImDJDNA (AG4 -AG6) of 3.5 kcal/mol.
Experimental values for the relative binding afities of Dst and 2-ImD have been determined using NMR spectroscopy, UV detected melting, and calorimetry. When the ligands Dst and 2-ImD are present in a 2-fold excess with the AAGTT oligomer, resonances from both the 2-ImDnDst-DNA complex and the Dst-Dst DNA complex can be seen in a ratio of about 15:1. This population difference corresponds to a AG of 1.6 kcal/mol difference (see Table 2 ) in binding free energy for 2-ImD relative to Dst at site I. This correlates reasonably well with the calculated value of 0.7 kcal/mol ( Table 2 ). The absence of resonances from the Dst-2-ImDIDNA and 2-ImD-2-ImDLDNA complexes indicates that these complexes are significantly higher in free energy, as also found by our calculations.
A comparison of the 2:1 complexes of Dst and 2-ImD can be made by using data from UV melting and titration calorimetry (D. Rentzeperis, L. Marky, B. Geierstanger, and D.E.W., unpublished results). In this case the accuracy is Table 2 ), which is in good agreement with the calculated value of 1.8 kcal/mol ( Table 2) .
The calculations presented here reproduced the correct rank order of stability of the different complexes, including that ofDst at the AAGTT site. The traditional ideas about Dst binding would have considered this to be an unfavorable site, since the amino group of G6 protrudes into the minor groove. However, in the 2:1 binding motif, this can easily be accommodated, yielding a complex with fairly high affinity. The affinity can be increased, again as reproduced well in the calculations, through the presence of specific ligand-DNA hydrogen bonds. The calculations also indicate that the desolvation of 2-ImD is a dominant unfavorable factor in its poor binding at site II, since there is no compensating hydrogen bond formed to the DNA.
The structure of the complex during the course of the FEP calculations remained fairly stable and in the vicinity of the NMR structure. This is reflected in the total rms deviations for all the atoms of the structure after 50 ps from the NMR structure (2.51 A). The major contribution to this deviation is from the structural changes in the base pair separations while very small changes take place in the DNA-drug interactions. All the hydrogen bonds between the peptide groups on the drug and the minor groove groups (02 of T7, T8, C17, T18, and T19 and N3 of G6 and A16) are preserved in the equilibrated structure and also in all the perturbed structures. Thus we note that the change in hydrogen-bonding interactions between the drug and the DNA takes place only between H21, the amino proton, of G6 and N3 of the ligand. The rms deviations of the structures after 50 ps of FEP at site I, site II, and sites I and II from the NMR structure are 2.53, 2.67, and 2.51 A, respectively. 
CONCLUSIONS

